ASCO 2024 | Advancing glioma treatment using autologous gamma-delta T cells
Mina Lobbous, MD, MPH, Case Western Reserve University, Cleveland, OH, envisions how gene-modified autologous (γδ) T cell-based immunotherapy can effectively target glioma stem cells upon intratumoral administration, considering the complex and immunosuppressive nature of the tumor microenvironment. Given in combination with temozolomide, treatment is more likely to be effective. Ongoing research in a Phase II study aims to provide further insights into its efficacy. Looking ahead, future treatments may involve the use of donor haploidentical stem cells to enhance therapeutic outcomes. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
